Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

Objective Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, is metabolized primarily by cytochrome P450 (CYP) 3A with minor contributions from CYP1A2, CYP2C19, and glucuronidation. Co-administration with CYP inhibitors may inc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Pithavala, Yazdi K., Tong, Warren, Mount, Janessa, Rahavendran, Sadayappan V., Garrett, May, Hee, Brian, Selaru, Paulina, Sarapa, Nenad, Klamerus, Karen J.
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2010
Matèries:
Phase I Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3256319/
https://ncbi.nlm.nih.gov/pubmed/20740300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9511-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars